Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081725 | 1.00 | SLC6A4 (0.42) | SLC6A4SLC6A2MEN1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4080033 | 0.85 | SLC6A2 (0.61) | SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL4080030 | 0.85 | SLC6A2 (0.61) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4087466 | 0.78 | SLC6A2 (0.49) | SLC6A4SLC6A2MEN1KMT2AL3MBTL1 | |
| SCHEMBL4087463 | 0.78 | SLC6A2 (0.49) | SLC6A4SLC6A2MEN1KMT2AL3MBTL1 | |
| SCHEMBL4717012 | 0.75 | SLC6A2 (0.49) | SLC6A4SLC6A2 | |
| SCHEMBL4090139 | 0.73 | SLC6A2 (0.71) | SLC6A4SLC6A2MEN1KMT2AL3MBTL1 | |
| SCHEMBL4716250 | 0.68 | SLC6A2 (0.48) | SLC6A4SLC6A2 | |
| SCHEMBL4090311 | 0.67 | SLC6A2 (0.52) | SLC6A4SLC6A2MEN1KMT2A | |
| SCHEMBL4082041 | 0.67 | SLC6A2 (0.56) | SLC6A4SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638512-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080255102-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-7414052-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1730127-B1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1732887-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1730127-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth, A Corporation of the State of Delaware (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005097744-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097761-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | SLC6A4 13/4885SLC6A2 8/4885MEN1 2681/4885 |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | SLC6A4 13/4885SLC6A2 8/4885MEN1 2681/4885 |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | SLC6A4 13/4885SLC6A2 8/4885MEN1 2681/4885 |
| US-20080255102-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | SLC6A4 8/4885SLC6A2 6/4885MEN1 2953/4885 |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | SLC6A4 13/4885SLC6A2 8/4885MEN1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.